CML Publications from Latin America

• The influence of the COVID-19 pandemic in NK cell subpopulations from CML patients enrolled in the Argentina Stop Trial
  Sanchez MB et al. Cells, April 2025 – open access publication
• The influence of the COVID-19 pandemic in NK cell subpopulations from CML patients enrolled in the Argentina Stop Trial
  Belén Sanchez M et al. Cells, April 2025 – open access publication
• Expression of HOTAIR and PTG2 as potential biomarkers in chronic myeloid leukemia patients in Brazil
  Kubaski Benevides AD et al. Front Oncol, Oct 2024 – open access publication
• Impact of a guaranteed access program to imatinib on the survival of patients with chronic myeloid leukemia
  Barranco G et al. Cancer Causes Control, Sept 2024 (epub ahead of print)
• Association between plasma imatinib levels and response to treatment of chronic myeloid leukemia in patients from Manaus, Brazil
  Henriques MA et al. J Oncol Pharm Pract, May 2024 (epub ahead of print)

• Long-term follow-up in patients with chronic myeloid leukemia treated with ponatinib in a real-world cohort: Safety and efficacy analysis
  Mela Osorio MJ et al. Clin Lymphoma Myeloma Leuk, October 2023 (epub ahead of print)
• Treatment-free remission in patients with chronic myeloid leukemia: recommendations of the LALNET expert panel
  Pavlovsky C et al. Blood Adv, December 2021 – open access publication
• Challenges in chronic myeloid leukemia management in South America
  Pagnano KB et al. Curr Hematol Malig Rep, October 2021 (epub ahead of print)
• Influence of genetic polymorphisms in glutathione-S-transferases gene in response to imatinib among Brazilian patients with chronic myeloid leukemia
  Delmond KA et al. Mol Biol Rep, March 2021 (epub ahead of print)
• COVID-19 in pediatric cancer patients in a resource-limited setting: National data from Peru
  Montoya J et al. Pediatr Blood Cancer, February 2021 – open access publication
• miRNome profiling of LSC-enriched CD34+ CD38- CD26+ fraction in Ph+ CML-CP samples from Argentinean patients: a potential new pharmacogenomic tool
  Sol Ruíz M et al. Front Pharmacol, January 2021 – open access publication
• Programme for harmonization to the International Scale in Latin America for BCR-ABL1 quantification in CML patients: Findings and recommendations
  Ruiz MS et al. Clin Chem Lab Med, May 2020 (epub ahead of print)
• Contributions of a regional approach to document hematologic disease in Mexico: a 10-year experience in an open population
  Jaime-Pérez JC. Hematology, December 2018
• Mutations in the breakpoint cluster region-Abelson murine leukemia 1 gene in Brazilian patients with chronic myeloid leukemia
  Costa HZ et al. Hematol Transfus Cell Ther, Oct – Dec 2018
• Chronic myeloid leukemia: What is the best strategy to start and monitor treatment outside academic centers?
  Pavlovsky C et al. Curr Oncol Rep, February 2018
• Chronic myelogenous leukemia: monitoring and predictors of a favourable response to treatment with imatinib
  Mela Osorio MJ et al. Medicina (B Aires) 2017;77(3):161-166
  (in Spanish)
• Guidelines for molecular monitoring of BCR-ABL in chronic myeloid leukemia patients by RT-q-PCR
  Larripa I et al. Medicina (B. Aires), 2017 (in Spanish)
• The age and sex frequencies of patients with leukemia seen in two reference centers in the metropolitan area of Mexico City
  Santoyo-Sánchez A et al. Gac Med Mex, Jan-Feb, 2017
  (in Spanish)